Imatinib mesylate in first-line treatment of chronic myeloid leukemia

Objective: Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by clonal proliferation of myeloid cells. Inthis study we aimed to present our experience in patients with CML who used imatinib mesylate, a tyrosine kinase inhibitor (TKI).Aim: Sixty nine patients who were diagnosed with CML and were treated with first-generation TKI ( in the form of imatinib mesylate)as initial treatment between 2006 and 2018 were included in this retrospective study. The demographic characteristics, responserates (hematologic, cytogenetic and molecular), adverse events and overall survival (OS) rates were retrospectively analyzed.Results: There were 28 male and 41 female patients with a median age of 49.3. Hematologic, cytogenetic and molecular responsesto TKI treatment were evaluated according to the 2013 guidelines of European Leukemia Net (ELN). The complete hematologicresponse (CHR) rate at three months was 97.1%, the complete cytogenetic response (CCR) rate at 12 months was 73.4%, and themajor molecular response (MMR) at 18 months was 77.8%. The most common adverse events were cytopenia (13%), edema (10.1%),nausea/vomiting (7.2%), and musculoskeletal pain (5.8%). The mean follow-up period was 40.4 months for all CML patients, with anoverall survival (OS) rate of 84.6% during follow-up.Conclusion: As a real life data in our population, our results were consistent with those reported in the literature. Drug-relatedadverse events were minimal and tolerable. Long-term survival and disease-free survival can be achieved with proper cytogeneticand molecular monitoring under imatinib treatment and, if necessary, a change in medication.

PDF

___

1. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. New Engl J Med 1999;341:164–72.
2. Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684-92.
3. Serpa M, Sanabani SS, Dorliac-Llacer PE, et al. Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. BMC Blood Disord 2010;10:7.
4. Hoffman R, Benz EJ, Shattil SJ, et al . Hematology basic principles and practice 5th Edition. Churchill, Livingstone, Elsevier; 2005. p.1247-53.
5. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2003:132-52.
6. Silver RT, Woolf SH, Hehlmann R, et al. An evidence -based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517- 36.
7. O Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
8. Hughes TP, Kaeda J, Branford S, et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of majör molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
9. Deininger M, O Brien SG, Guilhot F. et al. International randomized study of interferon vs. STI571 (IRIS) 8 year follow up: sustained survival and low risk for progression of events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:3376-81.
10. Cornelison AM, Kantarjian H, Cortes J, et al. Outcome of treatment of chronic myeloid leukemia with second- generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk 2011;11:101-10.
11. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96.
12. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in Chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567-76.
13. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012;120:1390-7.
14. Kantarjian HM, Cortes J, Guilhot F, et al. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer 2007;109:1365-75.
15. Sahin F, Saydam G, Cömert M, et al. Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turk J Haematol 2013;30:351-8.
16. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63:789-99.
17. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-8.
18. Saglio G, Kim DW, Issaragrisil S, et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9.
19. Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol 2010;47:302-11.
20. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997;96:111-6.
21. White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Curr Hematol Malig Rep 2009;4:59-65.
22. Karaman A, Solmaz Medeni S, Sevindik OG, ve ark. Kronik Myeloid Lösemi Tanılı Hastalarımızın Retrospektif Değerlendirilmesi. DEU Tip Fakultesi Dergisi 2016;30:103- 12
23. Zhao Y, Liu L, Wang Y, et al. Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. Int J Hematol 2009;89:445-51.
24. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012;120:3898-905.
25. Baccarani M, Deininger MW, Rosti G, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84.